Volition Proudly Sponsors the 44th ISICEM Congress

Core Viewpoint - VolitionRx Limited is participating as a silver sponsor at the 44th Annual ISICEM Congress in Brussels, showcasing its Nu.Q® H3.1 epigenetic screening technology, which has significant implications for sepsis care and critical care medicine [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics, dedicated to improving outcomes for patients with life-altering diseases through earlier detection and monitoring [9][10] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [10] Market Opportunity - The developments presented at ISICEM highlight a market opportunity exceeding $1 billion in sepsis care, positioning Volition at the forefront of advancements in critical care medicine [3] Presentations at ISICEM - Multiple presentations will feature the Nu.Q® H3.1 technology, including topics such as circulating NETs levels, functional endotyping in sepsis, and the role of H3.1 in early recognition of sepsis [3][4][5] - Notable speakers include Professor Djillali Annane and Professor Evangelos Giamarellos-Bourboulis, who will present on various aspects of sepsis and its management [4][5] Educational Impact - The ISICEM congress aims to enhance the care of critically ill patients through education and research, attracting over 5,000 participants globally [8]